Table 3.4. Factors to be considered when deciding on the best new antidiabetic treatment in coronary patients.

	SGLT2 inhibitors	GLP1-RA
Method of administration	Daily oral administration	Subcutaneous (oral semaglutide already exists, but is not yet available in Brazil) Daily or weekly administration
Benefits	Reduces MACE Reduces cardiovascular death (empagliflozin) Reduces HF Reduces (slightly) AP Prevents progression of nephropathy	Reduces MACE Reduces cardiovascular death (liraglutide) Weight loss Prevents progression of nephropathy (liraglutide)
Caution	Creatinine clearance < 30 mL/min/1.73 m² History of genital infections History of ketoacidosis Osteoporosis/fractures (canagliflozin) Peripheral arterial disease (canagliflozin)	Creatinine clearance <30 mL/min/1.73 m² Nausea History of pancreatitis Retinopathy (semaglutide)

MACE: major adverse cardiac events.